Please login to the form below

Not currently logged in
Email:
Password:

Allergan buys regenerative medicine firm LifeCell for $2.9bn

Acquired company focuses on plastic surgery and hernia repair procedures

Allergan logoAllergan has rounded off a particularly acquisitive 2016 – even by its own standards - with a $2.9bn deal to buy US regenerative medicine specialist LifeCell.

While most of the dozen deals Allergan has signed this year have been bolt-ons to bolster its pipeline, the purchase of LifeCell is somewhat different. The company is already making revenues from established products used for plastic surgery and hernia repair procedures, and is predicting sales will reach $450m this year – adding immediately to Allergan's top line.

Allergan chief executive Brent Saunders said the acquisition is "both strategically and financially compelling" and will "create a world-class aesthetic and regenerative medicine business in plastic surgery". In addition to its commercial products, Allergan also acquires LifeCell's manufacturing and R&D operations, based in New Jersey.
LifeCell's portfolio includes human skin repair product AlloDerm, fat-grafting device Revolve and porcine-based tissue matrix Strattice for abdominal wall repairs, and will slot in alongside the Dublin-headquartered company's own cosmetic pharmaceuticals. 

Those are headed by blockbuster wrinkle treatment Botox but also include Kybella - bought along with Kythera last year for $2.1bn - for reducing double chins and dermal filler Juvederm.

Allergan's other deals in 2016 have included a $1.7bn acquisition of Tobira Therapeutics - which gave it two drug candidates for non-alcoholic steatohepatitis (NASH) - a $639m takeover of dermatology specialist Vitae Pharmaceuticals as well as smaller deals such as the purchases of Akarna and Topokine. All of those deals involved companies with no revenues.

The company has been selling off assets to fund its acquisitive streak too, and earlier this year completed the $38.8bn divestment of its generic drugs business to Teva. 

The string of acquisitions followed Allergan's failed $160bn merger with Pfizer that was called off in April after a US government clampdown on tax inversion deals.

Article by
Phil Taylor

22nd December 2016

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
BASTARD . LONDON

BASTARD . LONDON collaborates with you to amplify brand ideas into a visual brand language that resonates and engages with...

Latest intelligence

Cell and gene therapy
Tackling the manufacturing cost and complexity challenges...
2019: CRISPR and therapeutic gene editing comes of age
Can gene-editing deliver safe and effective therapeutics for patients with intractable diseases?...
The 10-year Web Challenge
Understanding your users’ needs is more critical online today than ever. A site should mould itself around these insights, deliver those needs quickly, efficiently and with plenty of white space....

Infographics